Your browser doesn't support javascript.
loading
The quest for vaccine-induced immune correlates of protection against tuberculosis.
Nemes, Elisa; Fiore-Gartland, Andrew; Boggiano, Cesar; Coccia, Margherita; D'Souza, Patricia; Gilbert, Peter; Ginsberg, Ann; Hyrien, Ollivier; Laddy, Dominick; Makar, Karen; McElrath, M Juliana; Ramachandra, Lakshmi; Schmidt, Alexander C; Shororbani, Solmaz; Sunshine, Justine; Tomaras, Georgia; Yu, Wen-Han; Scriba, Thomas J; Frahm, Nicole.
Afiliação
  • Nemes E; South African Tuberculosis Vaccine Initiative, Division of Immunology, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
  • Fiore-Gartland A; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Boggiano C; National Institute of Allergy and Infectious Diseases, National Institutes of Health.
  • Coccia M; GSK.
  • D'Souza P; National Institute of Allergy and Infectious Diseases, National Institutes of Health.
  • Gilbert P; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Ginsberg A; Bill & Melinda Gates Foundation, Seattle, WA, USA.
  • Hyrien O; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Laddy D; IAVI.
  • Makar K; Bill & Melinda Gates Foundation, Seattle, WA, USA.
  • McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Ramachandra L; National Institute of Allergy and Infectious Diseases, National Institutes of Health.
  • Schmidt AC; Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USA.
  • Shororbani S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Sunshine J; Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USA.
  • Tomaras G; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.
  • Yu WH; Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USA.
  • Scriba TJ; South African Tuberculosis Vaccine Initiative, Division of Immunology, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
  • Frahm N; Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USA.
Vaccine Insights ; 1(3): 165-181, 2022 Jul.
Article em En | MEDLINE | ID: mdl-37091190
Immunization strategies against tuberculosis (TB) that confer better protection than neonatal vaccination with the 101-year-old Bacille Calmette-Guerin (BCG) are urgently needed to control the epidemic, but clinical development is hampered by a lack of established immune correlates of protection (CoPs). Two phase 2b clinical trials offer the first opportunity to discover human CoPs against TB. Adolescent BCG re-vaccination showed partial protection against Mycobacterium tuberculosis (Mtb) infection, as measured by sustained IFNγ release assay (IGRA) conversion. Adult M72/AS01E vaccination showed partial protection against pulmonary TB. We describe two collaborative research programs to discover CoPs against TB and ensure rigorous, streamlined use of available samples, involving international immunology experts in TB and state-of-the-art technologies, sponsors and funders. Hypotheses covering immune responses thought to be important in protection against TB have been defined and prioritized. A statistical framework to integrate the data analysis strategy was developed. Exploratory analyses will be performed to generate novel hypotheses.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article